摘要
Hepatitis C virus(HCV) is the leading indication for liver transplantation in the United States.It recurs universally after transplant but the rate of fibrosis and the development of graft failure is variable.Different donor and recipient features have been demonstrated to impact fibrosis.Plasma cell hepatitis,a histologic finding,is one feature associated with poor graft and patient outcomes.The pathogenic mechanism resulting in plasma cell hepatitis is poorly understood,with evidence suggesting a role for both the HCV and the immune system.A recent publication described plasma cell hepatitis in a larger context of immune medicated graft dysfunction in transplant recipients receiving interferon based therapy.This manuscript will highlight the topic of plasma cell hepatitis and provide commentary on the lack of recognition,the data regarding pathophysiologic mechanisms and the potential management options.
Hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States. It recurs universally after transplant but the rate of fibrosis and the development of graft failure is variable. Different donor and recipient features have been demonstrated to impact fibrosis. Plasma cell hepatitis, a histologic finding, is one feature associated with poor graft and patient outcomes. The pathogenic mechanism resulting in plasma cell hepatitis is poorly understood, with evidence suggesting a role for both the HCV and the immune system.A recent publication described plasma cell hepatitis in a larger context of immune medicated graft dysfunction in transplant recipients receiving interferon based therapy. This manuscript will highlight the topic of plasma cell hepatitis and provide commentary on the lack of recognition, the data regarding pathophysiologic mechanisms and the potential management options.
